Key result
Hemodialysis patients show ~14% lower serum vasohibin-1 than controls but no link to endothelial dysfunction.
Why the study?
Endothelial dysfunction is linked to high cardiovascular disease burden in hemodialysis patients, and vasohibin-1 may be a promising marker of endothelial dysfunction.
Are serum vasohibin-1 levels associated with markers of endothelial dysfunction in hemodialysis patients?
Case-Control (n=80)
Are serum vasohibin-1 levels associated with markers of endothelial dysfunction in hemodialysis patients?
Although serum vasohibin-1 levels are lower in hemodialysis patients, they do not correlate with traditional markers of endothelial dysfunction such as FMD, PWV, or CIMT.
Lower vasohibin-1 in HD lacks link to endothelial markers; leaves open biomarker role and needs prospective validation.
BACKGROUND: Endothelial dysfunction (ED) is associated with high cardiovascular disease burden in hemodialysis (HD) patients. Vasohibin-1, an endothelium-derived angiogenesis inhibitor, is essential for endothelial cell survival, therefore it may be a promising marker of ED. We aimed to investigate whether vasohibin-1 levels are associated with ED markers in HD patients. METHODS: Fifty HD patients and 30 healthy controls were included in the study. As markers of ED, endothelium-dependent flow-mediated dilatation (FMD), carotid intima-media thickness (CIMT), and pulse wave velocity (PWV) were examined. Serum vasohibin-1 levels were measured with ELISA. RESULTS: Serum vasohibin-1 levels were low (387.7 ± 115.7 vs 450.1 ± 140.1 P = .02), FMDs' were impaired (6.65 ± 2.50 vs 10.95 ± 2.86 P < .001), PWV (7.92 ± 1.964 vs 6.79 ± 0.96 P = .01) and CIMT (0.95 ± 0.20 vs 0.60 ± 0.11 P < .001) were increased in HD patients compared to healthy controls. In regression analysis, vasohibin-1 levels were not related with FMD, PWV, or CIMT. CONCLUSIONS: Hemodialysis patients have low serum vasohibin-1 levels but serum levels of vasohibin-1 did not show any significant relationship with FMD, PWV, and CIMT in HD patients. Since vasohibin-1 acts via paracrine pathways, serum levels may be insufficient to explain the relationship between vasohibin and ED. Local vasohibin-1 activity on tissue level may be more important instead of circulating levels.
No takes yet. Share an insight, caveat, or question.
Altunören et al. (2020) conducted a case-control in Hemodialysis (n=80). Hemodialysis vs. Healthy controls was evaluated on Serum vasohibin-1 levels (p=.02). Hemodialysis patients had significantly lower serum vasohibin-1 levels compared to healthy controls (387.7 vs 450.1; P=0.02), but levels did not correlate with endothelial dysfunction markers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: